CEL-SCI Shares Are Trading Higher After the Company Announced Results From a Bias Analysis Conducted for Its Concluded Phase 3 Study of Multikine. Multikine Cut the 5-year Risk of Death by Half Compared to Control in Its Target Population.
CEL-SCI Shares Are Trading Higher After the Company Announced Results From a Bias Analysis Conducted for Its Concluded Phase 3 Study of Multikine. Multikine Cut the 5-year Risk of Death by Half Compared to Control in Its Target Population.
cel-sci宣佈其多相應用研究的偏倚分析結果，multikine在目標人群中將5年死亡風險降低了一半，與對照組相比，cel-sci股價也因此有所上漲。
CEL-SCI Shares Are Trading Higher After the Company Announced Results From a Bias Analysis Conducted for Its Concluded Phase 3 Study of Multikine. Multikine Cut the 5-year Risk of Death by Half Compared to Control in Its Target Population.
cel-sci宣佈其多相應用研究的偏倚分析結果，multikine在目標人群中將5年死亡風險降低了一半，與對照組相比，cel-sci股價也因此有所上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。